A股異動 | 凱賽生物(688065.SH)漲超7%創8個月新高 生物基尼龍即將投產
格隆匯6月23日丨凱賽生物(688065.SH)大幅拉昇漲超7%,報103.71元創8個月新高價,成交額放大至2.36億元,總市值432億元。6月22日,公司官方發佈新聞,生物基戊二胺及生物基聚酰胺項目計劃於6月26至27日投產。據瞭解,調試相關樣品已經通過部分工程塑料和紡絲客户的驗證。新疆生物基戊二胺和生物基聚酰胺順利投產,將為山西合成生物產業園項目驗證技術和開拓市場。此外,公司計劃與山西轉型綜合改革示範區管理委員會合作在山西轉型綜合改革示範區投資打造“山西合成生物產業生態園區”,計劃總投資250億元,分期分步實施建設。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.